Results 191 to 200 of about 49,721 (234)
Nab-Paclitaxel related cystoid macular edema.
La Clinica terapeutica, 2022 Nab-paclitaxel is a chemotherapeutic drug used to treat various solid malignant tumors. It was conceived with a solvent free formulation to overcome toxicity events and hypersensitivity reactions associated with paclitaxel. However, it still carries ocular adverse effects.
Di Pippo, M +4 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nab-paclitaxel: A flattering facelift
Critical Reviews in Oncology/Hematology, 2014The application of nanotechnology in oncology has increased the efficacy and efficiency of some cytotoxic agents. The paradigm in this field is nab-paclitaxel, a soluble form of paclitaxel that is linked to albumin nanoparticles. The development of nanotechnology as a delivery system for paclitaxel has provided better pharmacokinetic and ...
Antonio Viudez, Natalia Ramirez
exaly +3 more sources
Metabolism of the taxanes including nab-paclitaxel
Expert Opinion on Drug Metabolism & Toxicology, 2014 The classical taxanes (paclitaxel, docetaxel), the newer taxane cabazitaxel and the nanoparticle-bound nab-paclitaxel are among the most widely used anticancer drugs. Despite years of research, the optimal dosing regimen (weekly vs 3-weekly) and optimal dose is still controversial, as is the value of pharmacological personalization of taxane dosing ...
Joerger M
openaire +4 more sources
Efficacy of nab-paclitaxel in treating metastatic melanoma
Expert Opinion on Pharmacotherapy, 2019 Systemic treatment of metastatic melanoma has been revolutionized by the advent of checkpoint inhibitors and targeted agents which are widely accepted as standard front-line therapies. However, despite these major advances, a substantial portion of patients still fail checkpoint inhibitors and/or targeted agents and are not candidates for clinical ...
Specenier, Pol
openaire +4 more sources
Safety and Efficacy of nab -Paclitaxel in the Treatment of Patients with Breast Cancer
Breast Cancer: Basic and Clinical Research, 2011 Taxanes are highly active chemotherapeutic agents in the treatment of early-stage and metastatic breast cancer. Novel formulations have been developed to improve efficacy and decrease toxicity associated with these cytotoxic agents.
Vivek Roy, Prakash Vishnu
exaly +2 more sources
Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel [PDF]
Gynecologic Oncology Case Reports, 2013 * First case report of successfully treating severe paclitaxel and docetaxel hypersensitivity reaction with nab-paclitaxel. * We demonstrated that nab-paclitaxel is a safe taxane chemotherapy treatment option for patients who could not tolerate ...
Giuseppe del Priore
exaly +2 more sources
Bulletin du Cancer, 2015
Resume Le paclitaxel est classiquement utilise dans un vaste eventail d’indications en oncologie. Le nab-paclitaxel est synthetise par un processus d’homogeneisation a haute pression du paclitaxel en presence d’albumine humaine et il a ete initialement developpe pour diminuer la toxicite generalement associee au cremophor du paclitaxel soluble et ...
Daniel Lopez-Trabada Ataz +2 more
openaire +1 more source
Resume Le paclitaxel est classiquement utilise dans un vaste eventail d’indications en oncologie. Le nab-paclitaxel est synthetise par un processus d’homogeneisation a haute pression du paclitaxel en presence d’albumine humaine et il a ete initialement developpe pour diminuer la toxicite generalement associee au cremophor du paclitaxel soluble et ...
Daniel Lopez-Trabada Ataz +2 more
openaire +1 more source
Nab-paclitaxel in patients with metastatic melanoma
Expert Review of Anticancer Therapy, 2015Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans. Until recently, progress in the treatment of metastatic melanoma remained dormant for nearly two decades. However, recent advances in immune and targeted therapeutic approaches have led to dramatic and paradigm-shifting advances in the management of metastatic ...
Roberto A, Leon-Ferre +1 more
openaire +2 more sources
Cystoid macular edema induced by nab-paclitaxel
Breast Cancer, 2012Cystoid macular edema (CME) is a rare complication of taxane-based chemotherapy. We encountered a patient who developed CME during treatment with nab-paclitaxel for metastatic breast cancer. Early detection of this disease enables continuation of appropriate treatment without reducing the quality of life for patients with end-stage disease.
Yuko, Tanaka +4 more
openaire +2 more sources
nab-Paclitaxel mechanisms of action and delivery
Journal of Controlled Release, 2013Taxanes are a key chemotherapy component for several malignancies, including metastatic breast cancer (MBC), ovarian cancer, and advanced non-small cell lung cancer (NSCLC). Despite the clinical benefit achieved with solvent-based (sb) taxanes, these agents can be associated with significant and severe toxicities.
openaire +2 more sources